作为内源性调节器的心脏慢性变异和内性变异 6-Cyanodopamine
José Britto-Júnior1, Antonio Tiago Lima1, Denis Lima Oliveira1
1Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Life sciences
|February 21, 2025
概括
老鼠的心脏释放出6-多巴胺,一种新型的甲醇胺. 这种物质显著增加了心率和收缩性,这表明它在心力衰竭和作为心脏脏疾病生物标志物的潜在治疗用途.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 在老鼠中,内皮衍生的6 - 尼特罗多巴胺诱导了积极的慢热和内热效应.
- 6 - 诺多巴胺是从子的心脏中释放出来的,但它的心脏作用是未知的.
- 在老鼠心脏中6 - 诺多巴胺的存在和功能需要调查.
研究的目的:
- 为了确定老鼠的隔离心室是否释放6-诺多巴胺.
- 为了研究6 - 诺多巴胺在老鼠隔离心脏上的慢性和内性作用.
- 探索6-诺多巴胺在心脏功能和疾病中的潜在作用.
主要方法:
- 液体染色学-双重质谱学 (LC-MS/MS) 用于基底6 - 诺多巴胺释放.
- 免疫组织化学和光在现场杂交 (FISH) 对于氨酸氧酶表达.
- 隔离心房和兰根多夫制剂用于评估慢性和异性效应.
主要成果:
- 鼠的隔离心室表现出基底释放的6-诺多巴胺,独立于四毒素.
- 在心脏内皮和心肌细胞中证实了氨酸氧酶的表达.
- 6-多巴胺 (10和100 pM) 显著增加了心房率和心脏收缩率 (LVDP,dP/dtmax).
- 6 - 诺多巴胺增强了诺亚上腺素对心脏功能的影响.
结论:
- 6 - 诺多巴胺是一种强大的内源性甲醇胺,在老鼠心脏中介导积极的慢性和异性反应.
- 6 - 诺多巴胺可能对心力衰竭具有治疗潜力.
- 这种新型的甲基荷胺可以作为心脏脏疾病的生物标志物.
相关概念视频
Heart Failure Drugs: Inotropic Agents
499
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
499
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Regulation of Heart Rates
1.5K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
1.5K
Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K


